Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

In patients with a progressive interstitial lung disease, 62% of whom had a CT pattern of usual interstitial pneumonia, those who received nintedanib had a lower annual rate of decline in the forced vital capacity than those who received placebo at 52 weeks.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-10, Vol.381 (18), p.1718-1727
Hauptverfasser:	Flaherty, Kevin R, Wells, Athol U, Cottin, Vincent, Devaraj, Anand, Walsh, Simon L.F, Inoue, Yoshikazu, Richeldi, Luca, Kolb, Martin, Tetzlaff, Kay, Stowasser, Susanne, Coeck, Carl, Clerisme-Beaty, Emmanuelle, Rosenstock, Bernd, Quaresma, Manuel, Haeufel, Thomas, Goeldner, Rainer-Georg, Schlenker-Herceg, Rozsa, Brown, Kevin K
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Carbon monoxide Computed tomography Diarrhea Diarrhea - chemically induced Disease Progression Double-Blind Method Female Fibrosis Genotype & phenotype Humans Idiopathic Pulmonary Fibrosis - drug therapy Idiopathic Pulmonary Fibrosis - physiopathology Indoles - adverse effects Indoles - therapeutic use Lung diseases Male Middle Aged Patients Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pulmonary fibrosis Quality of life Questionnaires Technical communication Tyrosine Vital Capacity - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In patients with a progressive interstitial lung disease, 62% of whom had a CT pattern of usual interstitial pneumonia, those who received nintedanib had a lower annual rate of decline in the forced vital capacity than those who received placebo at 52 weeks.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1908681